Lixte Biotechnology (NASDAQ:LIXT) Upgraded by Wall Street Zen to “Hold” Rating

Lixte Biotechnology (NASDAQ:LIXT) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings lowered Lixte Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 26th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Lixte Biotechnology Trading Down 14.6%

LIXT stock opened at $6.19 on Friday. The firm has a market capitalization of $92.97 million, a PE ratio of -5.48 and a beta of 1.27. Lixte Biotechnology has a 1-year low of $0.64 and a 1-year high of $7.51. The business’s 50 day simple moving average is $4.80 and its 200 day simple moving average is $3.92.

Lixte Biotechnology (NASDAQ:LIXT) last posted its earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its holdings in Lixte Biotechnology by 47.0% in the 4th quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock valued at $422,000 after buying an additional 34,350 shares in the last quarter. Federation des caisses Desjardins du Quebec grew its holdings in Lixte Biotechnology by 83.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after buying an additional 42,530 shares in the last quarter. DRW Securities LLC grew its holdings in Lixte Biotechnology by 11.6% in the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after buying an additional 5,645 shares in the last quarter. Geode Capital Management LLC grew its holdings in Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock valued at $205,000 after buying an additional 10,722 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Lixte Biotechnology in the 4th quarter valued at $57,000. 5.10% of the stock is owned by institutional investors and hedge funds.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.